European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care.

Screening for Atrial Fibrillation - A Cross-Sectional Survey of Healthcare Professionals in Primary Care. PLoS One (2016) 1.00

Neighbourhood socio-economic status and all-cause mortality in adults with atrial fibrillation: A cohort study of patients treated in primary care in Sweden. Int J Cardiol (2015) 0.79

Warfarin treatment and risk of stroke among primary care patients with atrial fibrillation. Scand Cardiovasc J (2016) 0.77

Warfarin treatment and risk of myocardial infarction - A cohort study of patients with atrial fibrillation treated in primary health care. Int J Cardiol (2016) 0.75

Stroke prevention in atrial fibrillation: we can do better. Br J Gen Pract (2016) 0.75

Stroke detection and prevention in atrial fibrillation. Br J Gen Pract (2015) 0.75

Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis. Eur J Prev Cardiol (2017) 0.75

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2007) 22.81

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke (1991) 22.23

Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet (2012) 20.09

Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39

A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med (2002) 16.31

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest (2009) 14.06

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (2013) 12.44

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J (2012) 12.36

Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49

Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11

Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med (2007) 10.87

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet (2007) 10.10

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet (2006) 9.43

A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med (2002) 8.37

Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70

Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet (2010) 6.31

Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ (2011) 5.84

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16

Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol (2010) 4.78

Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ (2001) 4.66

2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2011) 4.48

Stroke severity in atrial fibrillation. The Framingham Study. Stroke (1996) 4.11

Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke (2009) 3.89

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J (2012) 3.66

Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ (2007) 3.30

Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med (2012) 3.04

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med (2013) 2.84

A specific antidote for dabigatran: functional and structural characterization. Blood (2013) 2.77

Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol (2003) 2.73

Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72

Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation (2003) 2.61

A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess (2005) 2.42

Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost (2011) 2.35

A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med (2003) 2.04

Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke (1996) 1.94

Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation (2010) 1.93

Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.64

Increased atrial fibrillation mortality: United States, 1980-1998. Am J Epidemiol (2002) 1.63

Rising rates of hospital admissions for atrial fibrillation. Epidemiology (2003) 1.62

A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost (2011) 1.62

Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke (2001) 1.49

Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J (2009) 1.48

Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost (2011) 1.23

Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest (2013) 1.22

Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J (2003) 1.04

Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol (2012) 0.97

Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol (2012) 0.96

Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace (2014) 0.95

Is screening for AF worthwhile? Stroke risk in a screened population from the SAFE study. Fam Pract (2014) 0.94

Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. Circ Arrhythm Electrophysiol (2012) 0.93

Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation (2012) 0.92

Health-related quality of life in atrial fibrillation patients over 65 years: A review. Eur J Prev Cardiol (2014) 0.83

Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation. Int J Cardiol (2011) 0.79

Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants. Pharmacoeconomics (2013) 0.78